Andrew D. Zelenetz - Concepedia

Author

Andrew D. Zelenetz

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

A D Zelenetz, A Zelenetz, A. D Zelenetz, A. D. Zelenetz, A. Zelenetz, A.D. Zelenetz, ANDREW D. ZELENETZ, Adami, Hans-Olov, Andrew D Zelenetz, Andrew D. Zelenetz

757

Publications

42.4K

Citations

H-Index

167

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University The University of Texas MD Anderson Cancer Center Stanford University Dana-Farber Cancer Institute

About

Andrew D. Zelenetz is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	48	105	8.4K
2	Health Sciences	23	36	3.7K
3	Natural Sciences	5	5	459
4	Engineering	2	2	200
5	Nursing	1	1	15

Andrew D. Zelenetz

289

Publications

31.8K

Citations

H-Index

Page 1

	Year	Citations
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma Roland Schmitz, George W. Wright, Da Wei Huang, New England Journal of Medicine	2018	2.2K
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia Richard R. Furman, Jeff P. Sharman, Steven Coutré, New England Journal of Medicine	2014	1.7K
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee Elı́as Campo, Elaine S. Jaffe, James R. Cook, Blood ImmunologyPathologyInternational Consensus ClassificationDermatologyLymphoid Neoplasms	2022	1.4K
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era Zheng Zhou, Laurie H. Sehn, Alfred Rademaker, Blood	2013	934
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project Kenneth R. Carson, Andrew M. Evens, Elizabeth Richey, Blood	2009	866
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study Carla Casulo, Michelle Byrtek, Keith Dawson, Journal of Clinical Oncology	2015	818
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas Mark Kaminski, Andrew D. Zelenetz, Oliver W. Press, Journal of Clinical Oncology	2001	584
Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma Owen A. O’Connor, Craig H. Moskowitz, Jamie Muzzy, Journal of Clinical Oncology	2004	579
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis Adam M. Petrich, Mitul Gandhi, Borko Jovanovic, Blood	2014	461
Non-Hodgkin's Lymphomas Andrew D. Zelenetz, John C. Krauss, Pierluigi Porcu, Journal of the National Comprehensive Cancer Network Primary ImmunodeficiencyLymphoid NeoplasiaLymphocyte DevelopmentMediastinum NhlsImmunology	2011	457

Page 1